Tricuspid valve bioprosthesis EVOQUE

bovine tissuenitinolsutureless

A life-threatening condition like symptomatic severe TR deserves a revolutionary approach1 Medications may treat symptoms but not the TR itself, which can continue to progress. Reducing TR severity may improve patient quality of life.2,4 The EVOQUE valve has the potential to eliminate tricuspid regurgitation Move the arrow left or right to see the comparison between a heart with tricuspid regurgitation and one with the EVOQUE valve Meet the EVOQUE system The EVOQUE system is the world's first transcatheter tricuspid valve replacement therapy Learn about the EVOQUE valve Designed for anatomical compatibility Self-expanding, shape memory nitinol frame designed to conform to native valve anatomy Designed toseal within the native tricuspid annulus Intra-annularsealingskirt and frame Designed fora secure implantation Nine ventricularanchors engage leaflets, subvalvular anatomyand theannulus enabling a secure transcatheter placement ThermaFixtissue technology* Same bovine pericardial tissue as Edwards SAPIEN and PERIMOUNT valves* Multiple valve sizes to treat a broad range of tricuspid anatomies The TRISCEND II pivotal trial establishes TTVR as a new treatment option for patients with symptomatic ≥ severe TR The TRISCEND II trial is a prospective multi-center randomized controlled trial evaluating the safety and effectiveness of transcatheter tricuspid valve replacement with the EVOQUE system plus optimal medical therapy compared to optimal medical therapy alone in patients with symptomatic severe TR. These data pertain to the entire cohort of 400 patients at 1 year.